Prescient Therapeutics (ASX:PTX) Initiates Phase 2a PTX-100 Clinical Study
Clinical Study Milestone
Prescient Therapeutics Limited (ASX: PTX) has successfully completed the first Site Initiation Visit (SIV) for its Phase 2a clinical study of PTX-100, aimed at treating relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). The open-label study will assess two dosage levels of PTX-100 in approximately 40 patients, focusing on efficacy as the primary endpoint and safety as a secondary endpoint.
Future Study Plans
This initial site initiation marks the beginning of multiple study sites to be activated in Australia, the USA, and Europe. Prescient Therapeutics plans to achieve the First Patient In and Dosed (FPID) milestone in the upcoming weeks.
Executive Comments
CEO James McDonnell stated, “The completion of the first SIV for this study is a key milestone in our development of PTX-100 as a potential CTCL treatment. It is the first of multiple sites that will be initiated in Australia, the USA and Europe. We look forward to continuing our progress with more study site initiations and achieving the next milestone of First Patient In and Dosed (FPID) in the coming weeks.”
Chief Medical Officer Dr Marissa Lim added, “It is very exciting to reach this milestone of opening the first study site for the Phase 2a study of PTX-100 at the Epworth Freemasons Haematology Clinical Trial Unit. Professor Miles Prince, AM, a world leading expert in the treatment of patients with CTCL will be the Principal Investigator. We look forward to working with Professor Prince and his international medical colleagues around the globe as we advance the development of our first-in-class therapeutic candidate.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.